With no money to pay interest on debt, how many days we can survive? Sell before the news breaks
S
So the company is being audited?
S
New shares being printed
S
The whole company is worth a penny
D
Shorts are getting what they deserve here.
r
It was a good post. I have followed this company for years. They now have aggressive management, they will be looking for more acquisitions, revenue will continue to grow, earnings will follow, but current emphasis is revenue growth both internal and external. Hedge fund or Mutual fund might be behind the increased volume along with Buy Recommendation from Collier. Hot Sector.
o
long
D
Buyers 2/2/21 1,567,840 $18,108,552 39.10% A large institutional buy, this is significant because of the low issued share count of 11M
D
Bioanalytical Sys. initiated with a Buy at Colliers Securities; tgt $17 2:46 PM ET 12/22/20 | . Analyst Kyle Bauser said, "We are initiating coverage of Bioanalytical Systems (dba Inotiv) with a Buy rating and $17 Price Target. BASI is a contract research organization (CRO) that provides nonclinical and analytical contract research services to life science companies. Currently trading at roughly half the peer group average, we believe there is considerable upside to BASI shares, particularly given its premium growth rate. Following channel checks with several biotech companies, we learned that not only does BASI have a full range of service offerings, but the company's customer service and quality make it undoubtedly the best-in-class CRO. Our $17 Price Target assumes a 3.2x EV/sales multiple (peer group average) applied to $69.2M CY21E sales, $26.0M net debt, and 11.6M FD shares."
I
Stock is down over 50% in the past week or so. Anyone have any ideas why?
j
sold none today looks like we are gonna go parabolic now big move
Security and Exchange Commission SEC Bioanalytical Systems Inc Form 10-K
Security and Exchange Commission SEC Bioanalytical Systems Inc Form 10-K
sec.report
j
sold the rest today just under 5 great ride
D
I am liking my own posts since nobody else is. : )
T
I told you all last year to buy this at $4.
L
Another insider buying report after the close today - operations manager acquired shares at $3.45 yesterday.
D
The company will host it's inaugural conference call coinciding with it's next earning report. BASI (soon to be Inotiv) will be a solid long term winner.
D
CRO, do your DD. Not many CRO's trading at $9, like 0 besides this one. They all start down here and inevitably go up up up.
M
Why is the 52 week high 9.50 i dont see it hit that any were in the chart the past year
A large institutional buy, this is significant because of the low issued share count of 11M
2:46 PM ET 12/22/20 |
. Analyst Kyle Bauser said, "We are initiating coverage of Bioanalytical Systems (dba Inotiv) with a Buy rating and $17 Price Target. BASI is a contract research organization (CRO) that provides nonclinical and analytical contract research services to life science companies. Currently trading at roughly half the peer group average, we believe there is considerable upside to BASI shares, particularly given its premium growth rate. Following channel checks with several biotech companies, we learned that not only does BASI have a full range of service offerings, but the company's customer service and quality make it undoubtedly the best-in-class CRO. Our $17 Price Target assumes a 3.2x EV/sales multiple (peer group average) applied to $69.2M CY21E sales, $26.0M net debt, and 11.6M FD shares."
Annual Report From SEC on 10-K
https://sec.report/Document/0001104659-19-076191/